- Home
- ENPH vs RNA Comparison
ENPH vs RNA Comparison
Compare ENPH & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENPH
- RNA
- Stock Information
- Founded
- ENPH 2006
- RNA 2012
- Country
- ENPH United States
- RNA United States
- Employees
- ENPH N/A
- RNA N/A
- Industry
- ENPH Semiconductors
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- ENPH Technology
- RNA Health Care
- Exchange
- ENPH Nasdaq
- RNA Nasdaq
- Market Cap
- ENPH 4.2B
- RNA 4.0B
- IPO Year
- ENPH 2012
- RNA 2020
- Fundamental
- Price
- ENPH $37.63
- RNA $44.74
- Analyst Decision
- ENPH Hold
- RNA Strong Buy
- Analyst Count
- ENPH 31
- RNA 15
- Target Price
- ENPH $60.86
- RNA $71.00
- AVG Volume (30 Days)
- ENPH 7.6M
- RNA 3.3M
- Earning Date
- ENPH 10-21-2025
- RNA 11-06-2025
- Dividend Yield
- ENPH N/A
- RNA N/A
- EPS Growth
- ENPH 37.10
- RNA N/A
- EPS
- ENPH 1.28
- RNA N/A
- Revenue
- ENPH $1,482,823,000.00
- RNA $10,729,000.00
- Revenue This Year
- ENPH $12.60
- RNA N/A
- Revenue Next Year
- ENPH N/A
- RNA $110.16
- P/E Ratio
- ENPH $29.50
- RNA N/A
- Revenue Growth
- ENPH 4.39
- RNA 1.23
- 52 Week Low
- ENPH $29.89
- RNA $21.51
- 52 Week High
- ENPH $126.19
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- ENPH 53.07
- RNA 50.15
- Support Level
- ENPH $36.87
- RNA $35.70
- Resistance Level
- ENPH $39.85
- RNA $49.16
- Average True Range (ATR)
- ENPH 1.62
- RNA 2.63
- MACD
- ENPH 0.07
- RNA -0.88
- Stochastic Oscillator
- ENPH 48.25
- RNA 57.58
About ENPH Enphase Energy Inc.
Enphase Energy is a global energy technology company. It delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Enphase derives a majority of revenue from the United States.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.